Detalhe da pesquisa
1.
Metabolism-driven in vitro/in vivo disconnect of an oral ERÉ VHL-PROTAC.
Commun Biol
; 7(1): 563, 2024 May 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38740899
2.
The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance.
Cancer Res
; 83(23): 3989-4004, 2023 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37725704
3.
Discovery of a Potent and Orally Bioavailable Zwitterionic Series of Selective Estrogen Receptor Degrader-Antagonists.
J Med Chem
; 66(4): 2918-2945, 2023 02 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-36727211
4.
Combined p53 and MDM2 biomarker analysis shows a unique pattern of expression associated with poor prognosis in patients with renal cell carcinoma undergoing radical nephrectomy.
BJU Int
; 109(8): 1250-7, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21756282
5.
Accelerating the Validation of Endogenous On-Target Engagement and In Cellulo Kinetic Assessment for Covalent Inhibitors of KRASG12C in Early Drug Discovery.
ACS Chem Biol
; 17(8): 2366-2376, 2022 08 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-35881961
6.
AZD4625 is a Potent and Selective Inhibitor of KRASG12C.
Mol Cancer Ther
; 21(10): 1535-1546, 2022 10 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35930755
7.
MDM2 interacts with NME2 (non-metastatic cells 2, protein) and suppresses the ability of NME2 to negatively regulate cell motility.
Carcinogenesis
; 32(8): 1133-42, 2011 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-21504894
8.
Addition of Fluorine and a Late-Stage Functionalization (LSF) of the Oral SERD AZD9833.
ACS Med Chem Lett
; 11(12): 2519-2525, 2020 Dec 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33335676
9.
Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist.
J Med Chem
; 63(23): 14530-14559, 2020 12 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32910656
10.
Building Bridges in a Series of Estrogen Receptor Degraders: An Application of Metathesis in Medicinal Chemistry.
ACS Med Chem Lett
; 10(10): 1492-1497, 2019 Oct 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31620239
11.
Tricyclic Indazoles-A Novel Class of Selective Estrogen Receptor Degrader Antagonists.
J Med Chem
; 62(3): 1593-1608, 2019 02 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-30640465
12.
Combined Inhibition of PI3Kß and mTOR Inhibits Growth of PTEN-null Tumors.
Mol Cancer Ther
; 17(11): 2309-2319, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30097489
13.
Vasculogenic mimicry in small cell lung cancer.
Nat Commun
; 7: 13322, 2016 11 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27827359
14.
Senescence induction in renal carcinoma cells by Nutlin-3: a potential therapeutic strategy based on MDM2 antagonism.
Cancer Lett
; 353(2): 211-9, 2014 Oct 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-25067787
15.
Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer.
Clin Cancer Res
; 20(4): 926-937, 2014 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24277449
16.
Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer.
Nat Med
; 20(8): 897-903, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24880617
17.
MDM2 promotes cell motility and invasiveness through a RING-finger independent mechanism.
FEBS Lett
; 584(22): 4695-702, 2010 Nov 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-21034743
18.
p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets?
Cancer
; 116(4): 780-90, 2010 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20052733
19.
MDM2 regulates dihydrofolate reductase activity through monoubiquitination.
Cancer Res
; 68(9): 3232-42, 2008 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18451149